AG-221: Phase Ib/II started

Celgene began an open-label, international Phase Ib/II trial to evaluate once-daily oral AG-221 or AG-120 with subcutaneous Vidaza azacitidine given for

Read the full 214 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE